The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 04, 2022

Filed:

May. 24, 2017
Applicants:

Institut National DE LA Santé ET DE LA Recherche Médicale (Inserm), Paris, FR;

Assistance Publique-hôpitaux DE Paris, Paris, FR;

Université Paris-saclay, Saint-Aubin, FR;

Université DE Paris, Paris, FR;

Inventors:

Frank Griscelli, Villejuif, FR;

Ali Turhan, France, FR;

Annelise Bennaceur Griscelli, Villejuif, FR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 35/545 (2015.01); A61K 31/19 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 31/19 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 35/545 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55511 (2013.01);
Abstract

The inventors have developed a metastatic 4T1 breast tumor model in BALB/c mice. They have shown that the vaccination with xenogeneic embryonic stem cells in combination with valproic acid (VPA) generates a higher anti-tumoral response against breast cancer and inhibits metastasis development. They established that these responses are achieved only by the addition of valproic acid in the therapeutic regimen in comparison to the use ESCs or iPSCs alone. Thus, the inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to i) a population of pluripotent cells and ii) a compound selected from a group which activates MHC expression, as a combined preparation for use in a method for treating a subject suffering from a cancer, comprising a step of administering simultaneously, separately or sequentially to said subject a therapeutically amount thereof.


Find Patent Forward Citations

Loading…